05:06
PNH, The Role of Complement in PNH, and The Potential of Inhibiting Complement C3
02:08
About Autoimmune Hemolytic Anemia (AIHA)
04:47
AIHA, The Role of Complement in AIHA and The Potential for C3 Inhibition
01:06
APL-2 and C3 Inhibition
02:28
About Paroxysmal Nocturnal Hemoglobinuria (PNH)
01:49
The Complement System
X
About
Apellis is a clinical-stage biopharmaceutical company pioneering the development of novel therapeutic compounds to treat disease by inhibiting the complement system at the level of C3, the central protein in the complement cascade. We are currently conducting clinical trials around the world with our lead candidate APL-2, a complement C3 inhibitor. Our current clinical programs include ongoing phase 2 trials in autoimmune hemolytic anemia (AIHA) and complement-dependent nephropathies, and phase 3 trials in geographic atrophy (GA) and paroxysmal nocturnal hemoglobinuria (PNH).
Find Apellis online and on social media:
Website: apellis.com/
Twitter: www.twitter.com/apellispharma
LinkedIn: www.linkedin.com/company/apellis
Tags